Home / Senior Fellows / Dr. Zhong Yuan, MS, MD, PhD

Dr. Zhong Yuan, MS, MD, PhD

 

© PHOTOGRAPH of New Westminster College - Dr. Zhong Yuan, M.S., M.D., Ph.D. - Senior Fellow of New Westminster College - http://newwestminstercollege.ca

BIOGRAPHICAL SUMMARY: Dr. Zhong Yuan, MS, MD, PhD

Dr. Zhong Yuan is an Epidemiologist, Medical Doctor, and a Senior Fellow of New Westminster College. He earned a M.D. in Medicine in 1987 from Beijing Medical University, a M.S. in Epidemiology and Biostatistics in 1992 from the Medical College of Wisconsin, and a Ph.D. in Epidemiology and Biostatistics in 1999 from Case Western Reserve University. He has also attended the Harvard Strategic Leadership Program in 2010 at the Harvard Business School.

Dr. Yuan has an outstanding record of ethical leadership and since 2005 has served as Senior Director of Epidemiology at Janssen Research & Development, LLC in Titusville, New Jersey in the United States. His previous professional experience includes:

  • 2006-2012: Director, Pharmacoepidemiology, Janssen Research & Development, LLC in Titusville, New Jersey, USA
  • 2005-2006: Associate Director, Pharmacoepidemiology, Statistical Science, Janssen Research & Development, LLC in Titusville, New Jersey, USA
  • 2004-2005: Senior Biometrician, Biostatistics and Statistical Information System (BASIS), Clinical Development Program (CDP), Merck & Co., Inc., Horsham, Pennsylvania, USA
  • 2001-2004: Biometrician, BASIS, CDP, Merck & Co., Inc., Horsham, Pennsylvania, USA
  • 1999-2001: Senior Research Associate, Department of Epidemiology and Biostatistics, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA
  • 1993-1998: Biostatistician, Department of Epidemiology/Biostatistics, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA
  • 1992-1993: Biostatistician, Department of Epidemiology and Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
  • 1988-1990: Research Coordinator, Nancy Regional and University Hospital, Nancy, France
  • 1987-1988: Physician (Resident), Department of Cardiology, Beijing Friendship Hospital, Beijing, China

Dr. Yuan’s professional affiliations include:

  • 2005-present: Member and Journal Reviewer for Pharmacoepidemiology and Drug Safety, International Society for Pharmacoepidemiology
  • 1997-2001: Member, Society for Epidemiological Research

Dr. Yuan’s honours and awards include:

  • 2012: Senior Fellow of New Westminster College in recognition of an outstanding record of ethical leadership, Vancouver, British Columbia, Canada
  • 2012: Global Leadership Profile Award in recognition of achieving exceptional results by demonstrating outstanding behaviors embodied in the tenets of the Global Leadership Profile, Janssen R&D
  • 2012: Encore Award in recognition of the special achievement in ATLAS NDA submission, J&J PRD
  • 2011: Global Leadership Profile Award in recognition of achieving exceptional results by demonstrating outstanding behaviors embodied in the tenets of the Global Leadership Profile, Janssen R&D
  • 2011 Global Leadership Profile Award in recognition of achieving exceptional results by demonstrating outstanding behaviors embodied in the tenets of the Global Leadership Profile, Janssen R&D
  • 2010: Global Leadership Profile in recognition of achieving exceptional business results by demonstrating outstanding behavior embodied in the tenets of Global Leadership Profile, J&J PRD
  • 2009: Standards of Leadership Award in recognition of achieving exceptional business results by demonstrating outstanding behavior in the tenets of Business Results and Customer/Market Focus for Rivaroxaban FDA Advisory Committee, J&J PRD
  • 2009: Encore Award for exhibiting achieves results and demonstrates customer focus by contributing to completion of ROCKET enrollment, J&J PRD
  • 2009: Standards of Leadership Award in recognition of achieving exceptional business results by demonstrating outstanding Pharmacoepidemiology Leadership for Priligy MAA EU Approval MAA, J&J PRD
  • 2008: Standards of Leadership Award in recognition of achieving exceptional business results by demonstrating outstanding Preparation of Post-Approval Studie, RMP Revision, and Response to the Dapoxetine DCP PrAR, J&J PRD
  • 2007: Standards of Leadership Award in recognition of achieving exceptional business results by demonstrating outstanding Pharmacoepidemiology Consultation for the Dapoxetine MAA, J&J PRD
  • 2007: Encore Award for exhibiting customer focus, strategic thinking, risk taking, judgment, and achieving results by contributing to Rocket AF SAP, J&J PRD
  • 2007: Encore Award for exhibiting strategic thinking, business acumen, and achieving results by developing Galaxy Data Usage Policy, J&J PRD
  • 2007: Encore Award in recognition of special achievement in RMP/ADR Epidemiology Leadership, J&J PRD
  • 2007: Standards of Leadership Award in recognition of achieving exceptional business results by demonstrating outstanding Leadership Behavior associated with the Rivaroxaban program, J&J PRD
  • 2006: Encore Award for special contribution in the Dapoxetine Program, J&J PRD
  • 2005: Vision Award in recognition of setting standard for performing innovative analyses for the Dapoxetine Program, J&J PRD
  • 2003: Award for Excellence for the SAFARI study, CDP, Merck Co. & Inc.
  • 2002: Award for Excellence for the CHESS study, CDP, Merck Co. & Inc.
  • 1990-1992: Full Academic Scholarship, Medical College of Wisconsin, Milwaukee, Wisconsin

Dr. Yuan’s manuscript publications include:

  • Gibson CM, Levitan B, Murphy SA, Yuan Z, Chakrabarti AK, Lee M, Mega J, Braunwald E. A Comparison of Fatal or Irreversible Bleeding and Ischemic Events in ATLAS ACS 2 – TIMI 51 (To be submitted)
  • Levitan B, Yuan Z, Turpie AGG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein R, DiBattiste PM. FACCBenefit–Risk Evaluation of Rivaroxaban versus Enoxaparin for the Prevention of Venous Thromboembolism after Total Hip or Knee Arthroplasty (Submitted)
  • Yuan Z, Levitan B, Berlin JA. Benefit-Risk Assessment: To quantify or Not to Quantify, That is the Question. Pharmacoepidemiology Drug Saf 2011; 20(6):653-6. doi: 10.1002/pds.2149.
  • Yuan Z. Weinstein R, Zhang Z, Cheng M, Griffin G, Zolynas R, Plotnikov A, Lee M, Oppenheimer L, Burton P.  Antithrombotic Therapies in Patients with Incident Heart Failure: hypothesis formulation from a research database.  Pharmacoepidemiol Drug Saf 2010;19(9):911-20.
  • Miller M, Dobs A, Yuan Z, Battisti WP, Palmisano J.  The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE Trial Sub-study.  Curr Med Res Opin 2006;22(2):343-50.
  • Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J.  Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study.   Am Heart J 2005;149(3):464-73.
  • Grundy SM, Vega GL, Yuan Z, Battisti W, Brady WE, Palmisano J.  Treatment of Combined Hyperlipidemia With Simvastatin Plus Fenofibrate.  Am J Cardiol 2005;95:462-468.
  • Miller M, Dobs A, Borisute H, Yuan Z, Battisti W, Palmisano J.  Effectiveness of Simvastatin Therapy in Raising HDL-C in Patients with Type 2 Diabetes and Low HDL-C.   Current Medical Research and Opinion 2004; 20:1087-1094.
  • Ballantyne CM, Blazing MA, Hunninghake DB, Davidson MH, Yuan Z, DeLucca PT, Ramsey KE, Hustad CM, Palmisano J.  Effect on high-density cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the comparative HDL efficacy and safety study (CHESS).  Am Heart J 2003; 146:862-9.
  • Cooper GS, Yuan Z, Jethva RN, Rimm AA. Use of Medicare claims data to measure county-level variation in breast carcinoma incidence and mammography rates.  Cancer Detect Prev 2002; 26(3):197-202.
  • Cooper GS, Yuan Z, Chak A, Rimm AA.  Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia. Cancer 2002; 95(1): 32-8.
  • Yuan Z, Dawson N, Cooper GS, Einstadter D, Cebul RD, Rimm AA.  Effect of Alcohol-Related Disease on Hip Fracture and Mortality: A Retrospective Cohort Study of 876,337 Hospitalized Medicare Beneficiaries.  AM J Public Health 2001;91:1089-1093.
  • Cooper GS, Yuan Z, Jethva RN, Rimm AA.  Determination of county-level prostate carcinoma incidence and detection rates with Medicare claims data.  Cancer 2001; 92(1): 102-9.
  • Biblo LA, Yuan Z, Quan KJ, Mackall JA, Rimm AA.  The Risk of Stroke in Patients with Atrial Flutter.  Am J Cardio 2001; 87(3): 346-9.
  • Yuan Z, Cooper GS, Einstadter D, Cebul RD, Rimm AA.  The Association Between Hospital Type and Mortality and Length of Stay: A Study of 16.9 Million Hospitalized Medicare Beneficiaries.  Medical Care 2000;38:231-245.
  • Cooper GS, Yuan Z, Chak A, Rimm AA.  Pattern of endoscopic follow-up after surgery for nonmetastatic colorectal cancer.  Gastrointest  Endosc 2000;52:33-38.
  • Cooper GS, Yuan Z, Stange KC, Dennis LK, Amini SB, Rimm AA.  Agreement of Medicare Claims and Tumor Registry Data for Assessment of Cancer Related Treatment.  Medical Care 2000; 38(4): 411-21.
  • Cooper GS, Yuan Z, Veri Laura, Rimm AA, Stange KC.  Colorectal Carcinoma Screening Attitudes and Practices among Primary Care Physicians in Counties at Extremes of Either high or Low Cancer Case-Fatality.  Cancer 1999;86:1669-74.
  • Cooper GS, Yuan Z, Dennis L, Stange KC, Dennis LK, Amini SB, Rimm AA.  The Utility of Medicare Claims Data for Measuring Cancer Stage.  Medical Care 1999;37:706-11.
  • Cooper GS, Yuan Z, Dennis L, Stange KC, Dennis LK, Amini SB, Rimm AA.  The Sensitivity of Medicare Claims Data for Case Ascertainment of Six Common Cancers.  Medical Care 1999;37:436-44.
  • Cooper GS, Yuan Z, Chak A, Rimm AA.  Geographic and Patient Variation among Medicare Beneficiaries in The Use of Follow-Up Testing after Surgery for Nonmetastatic Colorectal Cancer.  Cancer 1999;85:2124-31.
  • Yuan Z, Bowlin SJ, Einstadter D, Cebul R, Connors AF, Rimm AA.  Atrial Fibrillation as A Risk Factor for Embolic and Non-embolic Stroke: A Retrospective Cohort Study of Hospitalized Medicare Beneficiaries.  Am J Public Health 1998;88:395-400.
  • Cooper GS, Yuan Z, Stange KC, Dennis LK, Amini SB, Rimm AA.  Use of Medicare Claim Data to Measure County-Level Variation in the Incidence of Colorectal Carcinoma.  Cancer 1998;83:673-8.
  • Cooper GS, Yuan Z, Bowlin SJ, Dennis LK, Kelly R, Chen H, Rimm AA.  An Ecological Study of the Effectiveness of Mammography in Reducing Breast Cancer Mortality.  Am J Public Health 1998;88:281-4.
  • Cooper GS, Yuan Z, Rosenthal GE, Chak A, Rimm AA.  Lack of Gender and Racial Differences in Surgery and Mortality in Hospitalized Medicare Beneficiaries with Bleeding Peptic Ulcer.  J Gen Intern Med 1997;12(8):485-90.
  • Cooper GS, Yuan Z, Rimm AA: Racial Disparity in the Incidence and Case-Fatality of Colorectal Cancer: Analysis of 329 U.S. Counties. Cancer Epidemiology, Biomarkers & Prevention 1997;6(4):283-5.
  • Taylor CL, Yuan Z, Selman WR, Ratcheson RA, Rimm AA.  Mortality Rates, Hospital Length of Stay, and The Cost of Treating Subarachnoid Hemorrhage in Older Patients: Institutional and Geographical Differences.  J Neurosurg 1997;86:583-8.
  • Rahman MI, Gibson-Shreve LD, Yuan Z, Morris HA.  Cholelithiasis, Cholecystectomy and the Risk of Colorectal Cancer: Selections from Current Literature.  J Fam Pract 1996;13(5):483-7.
  • Rahman MI, Chagoury ME, Yuan Z, Fischler AR.  PSA Screening for Prostate Cancer: Selections from Current Literature.  J Fam Pract 1996;13(6):544-9.
  • Amini SB, Weight SA, Yuan Z, Rimm AA.  Abdominal and Vaginal Radical Hysterectomy among US Women Age 65 Years and Older.  Int J Technology Assessment in Health Care 1996;12(2):377-87.
  • Cooper GS, Yuan Z, Landefeld CS, Rimm AA.  Surgery for Colorectal Cancer: Race-Related Differences in Rates and Survival among Medicare Beneficiaries.  Am J Public Health 1996;86(4):582-6.
  • Taylor CL, Yuan Z, Selman WR, Ratcheson RA, Rimm AA.  Cerebral Arterial Aneurysm Formation and Rupture in 20,767 Elderly Patients: Hypertension and Other Risk Factors.  J Neurosurg 1995;83(5):812-9.
  • Hartz AJ, Kuhn EM, Yuan Z, Bailey RC, Rimm AA.  Adequacy of National Mortality Data for Internal Hospital Use: A Case Study.   Int J for Quality in Health Care 1995;7(2):109-18.
  • Cooper GS, Yuan Z, Landefeld CS, Johanson J, Rimm AA.  A National Population-Based Study of Incidence of Colorectal Cancer and Age. Implication for Screening in Older Americans.  Cancer 1995;75:775-81.
  • Oldridge NB, Yuan Z, Stoll JE, Rimm AA.  Lumbar Spine Surgery and Mortality among Medicare Beneficiaries, 1986.  Am J Public Health 1994;84(8):1-7.
  • Adams WL, Yuan Z, Barboriak JJ, Rimm AA.  Alcohol-Related Hospitalizations of Elderly People.  JAMA 1993;270(10):1222-5.

Dr. Yuan’s published abstracts and presentations include:

  • Yuan Z, Levitan B, Berlin JA.  Benefit-Risk Assessment: A Brief Review and An Example of A Quantitative Approach (presented at the 2012 ASA Biopharmaceutical Section FDA-Industry Workshop in Washington, DC)
  • Levitan B, Yuan Z. Pragmatic Considerations for Endpoint Selection and Display in Benefit-Risk Assessment. (presented at the 2012 ASA Biopharmaceutical Section FDA-Industry Workshop in Washington, DC)
  • Gibson CM, Levitan B, Murphy SA, Yuan Z, Chakrabarti AK, Lee M, Mega J, Braunwald E. A Net Clinical Outcome Analysis Comparing Fatal or Irreversible Ischemic and Hemorrhagic Events in ATLAS ACS 2 – TIMI 51 (2012-SS-A-13152-AHA)
  • Okumura K, Inoue H, Yasaka M, Gonzalez JM, Hauber AB, Iwamoto K, Wang ECY, Rossi B, Levitan B, Yuan Z, Briere JB. Japanese patients and physicians preferences for anticoagulants use in atrial fibrillation – Results from a conjoint-analysis study (ISPOR 15th Annual European Congress, November 2012, in Berlin, Germany.)  
  • Levitan B, Yuan Z, Turpie AGG, et al. Quantitative Benefit–Risk Assessment of Rivaroxaban for the Prevention of Venous Thromboembolism. Presented at Amer Soc Hematol, New Orleans, 2009. Published abstract 23356.
  • Yuan Z, Berlin J, Cohen S. Current Status of Drug-Eluting vs Bare-Metal Stents: Interpreting the Data. Presented at the FDA/Industry Statistics Workshop, Washington, D.C., September 23-25, 2009.
  • Yuan Z, Weinstein R, Zhang Z, Cheng M, Griffin G, Zolynas R, Plotnikov A, Lee M, Oppenheimer L, Burton P.  Clinical Outcomes Associated with Antithrombotic Therapies in Patients with Incident Heart Failure: A Retrospective Analysis of A Population-based Database.  Presented at the 24th International Conference on Pharmacoepidemiology and Drug Safety in August 2008, Copenhagen, Denmark.
  • Yuan Z, Jesse Berlin.  Consideration of Risk Evaluation Strategies in Clinical Trials.  Invited Speaker. Presented at the 2nd Modern Drug Discovery and Development Summit (Drug Safety & Pharmacovigilance) track on December 4-6 in Philadelphia, PA, 2006.
  • Ballantyne CM, Abate N, King TR, Yuan Z, Palmisano J.  Attainment of Optimal National Cholesterol Education Program Adult Treatment Panel III Treatment Goals in High Risk Patients: Dose Comparison of VYTORIN (Ezetimibe/Simvastatin) and Atorvastatin.  (Accepted to ACC 2005.  Submitted to ESC and EAS 2005)
  • Ballantyne CM, Abate N, King TR, Yuan Z, Palmisano J.  Evaluation of Ezetimibe/Simvastatin Versus Atorvastatin on Atherogenic Ratios (submitted to ESC and EAS, 2005).
  • Ballantyne CM, Abate N, King TR, Yuan Z, Palmisano J.  Evaluation of the Safety and Efficacy of Ezetimibe/Simvastatin (E/S) Combination Tablet Versus Atorvastatin (A) in Patients with Hypercholesterolemia.  Presented at DALM in Venice, Italy; October 2004.
  • Miller M, Dobs A, Battisti W, Yuan Z,  Palmisano J. Simvastatin Improves Triglyceride-Rich Lipoproteins in Patients with Type 2 Diabetic Dyslipidemia.  (Submitted to AHA, New Orleans, November 2004)
  • Grundy, SM, Vega GL, Yuan Z, Battisti W, Palmisano J.  Effect on LDL pattern distribution of treatment with simvastatin plus fenofibrate in patients with combined hyperlipidemia.  Presented at ADA, Orlando, Florida; June 2004.
  • Grundy, SM, Vega GL, Yuan Z, Battisti W, Palmisano J.  Treatment of combined hyperlipidemia with simvastatin plus fenofibrate.  Presented at ADA, Orlando, Florida; June 2004.
  • Grundy, SM, Vega GL, Yuan Z, King T, Palmisano J.  Effect of treatment with simvastatin plus fenofibrate on triglycerides-rich lipoprotein profile in patients with and without the metabolic syndrome.  Presented at ES; May 2004.
  • Grundy SM, Vega GL, Borisute H, Brady WE, Ramsey K, Battisti W, Yuan Z, Palmisano J.   Treatment of Combined Hyperlipidemia with Simvastatin Plus Fenofibrate.  Presented at the International TG’s meeting, New York, 2003.
  • Miller M, Borisute H, Yuan Z, Battisti W, Palmisano J.  Simvastatin significantly raised HDL-C in patients with Type 2 diabetic dyslipidemia and low HDL-C.  Presented at the American Diabetes Association 63rd Scientific Session, New Orleans, Louisiana, 2003.
  • Miller M, Dobs A, Borisute H, Yuan Z, Ramsey K, Gergich K, Spigle W, Battisti W, Palmisano J.  Simvastatin significantly raised HDL-C in patients with Type 2 diabetic dyslipidemia and low HDL-C.  Presented at the European Society of Cardiology, Vienna, Austria, 2003.
  • Ballantyne CM, Hustad CM, Yuan Z, DeLucca PT, Palmisano J.  Differential Effects of statins on high-density lipoprotein cholesterol in hypercholesterolemic patients with the metabolic syndrome.  Presented at the EASD, Budapast, Hungry, 2002.
  • Ballantyne CM, Hustad CM, Yuan Z, DeLucca PT, Palmisano J.  Efficacy and safety of simvastatin and atorvastatin: results of the comparative HDL efficacy and safety study (CHESS).  Presented at European Society of Cardiology (ESC), Berlin, Germany, 2002.
  • Yuan Z, Biblo L, Bowlin S, Rimm AA: Atrial flutter, a risk factor for stroke.   Presented in ACC 46th annual scientific session, 1997.
  • Russo L, Curley C, Yuan Z, Singer M.  Cost-effectiveness of Drugs vs. Psychotherapy for Moderate Depression in the Primary Care Setting.  American Journal of Managed Care 1997; March (3): S25.
  • Amini SB, Weight S, Yuan Z, Rimm AA: Abdominal and Vaginal Radical Hysterectomy among US Women Age 65 and Older. Int Society of Technology Assessment in Health Care, Stockholm, Sweden, 1995.
  • Taylor AL, Yuan Z, Rimm AA. Interactional effects of gender, race, and age on survival after myocardial infarction in a Medicare cohort. American Heart Association, Scientific Sessions for Medical and Nursing Research, California, Nov. 1995.
  • Yuan Z, Bowlin SJ, Einstadter D, Cebul R, Connors AF, Rimm AA: Atrial fibrillation as a risk factor for embolic and non-embolic stroke: a population-based study in the elderly. Presented and published in abstract form in Medical Decision Making 1994;14:444.
  • Yuan Z, Oldridge N, Rimm AA: Geographic variation in breast cancer. Presented in a poster session in Society for Cancer Epidemiology, Milwaukee division, 1991.
  • Yuan Z, Rimm AA. Breast cancer and alcohol consumption: an ecological analysis. Orally presented in a symposium for breast cancer research in Medical College of Wisconsin, 1991.
  • Cooper GS, Yuan Z, Chak A, Rimm AA. Use of endoscopic follow up after surgery for nonmetastatic colorectal cancer.  Submitted.
  • Cooper GS, Yuan Z, Chak A, Rimm AA.  Variation in use of follow up testing after surgery for nonmetastatic colorectal cancer. 

As a Senior Fellow of New Westminster College, Dr. Zhong Yuan is dedicated to supporting the highest standards of academic excellence and is committed to the advancement of New Westminster College and its Global Network of Fellows.

 
 
 
 

Leave a Comment

 

You must be logged in to post a comment.